[go: up one dir, main page]

WO2011024056A3 - An improved process for the preparation of bosentan - Google Patents

An improved process for the preparation of bosentan Download PDF

Info

Publication number
WO2011024056A3
WO2011024056A3 PCT/IB2010/002090 IB2010002090W WO2011024056A3 WO 2011024056 A3 WO2011024056 A3 WO 2011024056A3 IB 2010002090 W IB2010002090 W IB 2010002090W WO 2011024056 A3 WO2011024056 A3 WO 2011024056A3
Authority
WO
WIPO (PCT)
Prior art keywords
bosentan
preparation
improved process
deshydroxyethyl
sulfonamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2010/002090
Other languages
French (fr)
Other versions
WO2011024056A2 (en
Inventor
Kumar Sinha Brajesh
Rajasekhara Raju Konduru
Shankar Reddy Budidet
Pandu Rangarao Vaddi
Islam Aminul
Sivakumaran Meenakshisunderam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurobindo Pharma Ltd
Original Assignee
Aurobindo Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobindo Pharma Ltd filed Critical Aurobindo Pharma Ltd
Publication of WO2011024056A2 publication Critical patent/WO2011024056A2/en
Publication of WO2011024056A3 publication Critical patent/WO2011024056A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present application provides purification of Bosentan crude by making its crystalline potassium salt, which is further converted to Bosentan (I) with bis-sulfonamide (VIII) and deshydroxyethyl (IX) impurities to less than 0.2% by HPLC analysis.
PCT/IB2010/002090 2009-08-27 2010-08-27 An improved process for the preparation of bosentan Ceased WO2011024056A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2065/CHE/2009 2009-08-27
IN2065CH2009 2009-08-27
IN2132CH2010 2010-07-28
IN2132/CHE/2010 2010-07-28

Publications (2)

Publication Number Publication Date
WO2011024056A2 WO2011024056A2 (en) 2011-03-03
WO2011024056A3 true WO2011024056A3 (en) 2011-05-19

Family

ID=43033160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/002090 Ceased WO2011024056A2 (en) 2009-08-27 2010-08-27 An improved process for the preparation of bosentan

Country Status (1)

Country Link
WO (1) WO2011024056A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130245259A1 (en) * 2012-03-16 2013-09-19 Natco Pharma Limited Process for the preparation of bosentan monohydrate
JP2015521594A (en) * 2012-06-12 2015-07-30 カディラ ファーマシューティカルズ リミテッド Method for producing bosentan
CN104193687B (en) * 2014-07-01 2017-09-26 上海天慈国际药业有限公司 A kind of preparation method for treating pulmonary hypertension medicine
TWI835843B (en) 2018-10-03 2024-03-21 瑞士商亨斯邁紡織染化（瑞士）有限公司 New pyridine- and pyrimidine-substituted triazine uv absorbers

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292740A (en) * 1991-06-13 1994-03-08 Hoffmann-La Roche Inc. Sulfonamides
EP2072503A2 (en) * 2007-12-18 2009-06-24 Dipharma Francis S.r.l. Process for the preparation of bosentan
WO2009093127A2 (en) * 2008-01-24 2009-07-30 Actavis Group Ptc Ehf Substantially pure and a stable crystalline form of bosentan
WO2009095933A2 (en) * 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
WO2010032261A1 (en) * 2008-08-12 2010-03-25 Cadila Healthcare Limited Process for preparation of bosentan
WO2010103362A2 (en) * 2009-03-11 2010-09-16 Sifavitor S.R.L. Process for the preparation of bosentan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136971A (en) 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292740A (en) * 1991-06-13 1994-03-08 Hoffmann-La Roche Inc. Sulfonamides
EP2072503A2 (en) * 2007-12-18 2009-06-24 Dipharma Francis S.r.l. Process for the preparation of bosentan
WO2009095933A2 (en) * 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
WO2009093127A2 (en) * 2008-01-24 2009-07-30 Actavis Group Ptc Ehf Substantially pure and a stable crystalline form of bosentan
WO2010032261A1 (en) * 2008-08-12 2010-03-25 Cadila Healthcare Limited Process for preparation of bosentan
WO2010103362A2 (en) * 2009-03-11 2010-09-16 Sifavitor S.R.L. Process for the preparation of bosentan

Also Published As

Publication number Publication date
WO2011024056A2 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
WO2009095933A3 (en) Improved and novel process for the preparation of bosentan
WO2009004643A3 (en) An improved process for preparation of (s)-pregabalin and intermediates thereof
PH12012500634A1 (en) Processes for preparing of glucopyranosyl -substituted benzyl -benzene derivatives
AR078062A1 (en) HIGH TEMPERATURE LIGNINA SEPARATION PROCEDURE
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
MX2013011257A (en) Process for preparation of dronedarone by n-butylation.
AU2008258588A8 (en) Anti -inflammatory substituted cyclobutenedione compounds
WO2011024192A3 (en) Novel polymorphs of raltegravir
WO2010064109A3 (en) An improved process for the preparation of montelukast sodium and its intermediates
WO2012031045A3 (en) Phosphonate ester derivatives and methods of synthesis thereof
IN2012DN05209A (en)
PT2462098E (en) Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
MY155284A (en) Process for the preparation of ajoene
WO2011024056A3 (en) An improved process for the preparation of bosentan
MX2011009898A (en) Process for the preparation of propionic acid derivatives.
WO2009062659A3 (en) Polymorphs of enantiopure erdosteine
WO2010011748A3 (en) Synthetic intermediates and processes
UA106988C2 (en) A method of obtaining of 1-benzyl-3-hydroxymethyl-1h-indazole and its derivatives and required intermediate magnesium compounds
WO2009116081A3 (en) An improved process for the preparation of aprepitant
WO2011058524A3 (en) Crystalline forms of bosentan salts and processes for their preparation
WO2008094617A3 (en) Crystalline forms of deferasirox
WO2010107993A3 (en) Process for preparing (r)-7v-benzyl-2- (benyloxycarbonylamino)-s-methoxypropionamide
WO2007143014A3 (en) Methods for preparing glutamic acid derivatives and intermediates thereof
WO2008096373A3 (en) Process for synthesizing highly pure nateglinide polymorphs
GR1007722B (en) Process for the preparation of aripirazole

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10763229

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10763229

Country of ref document: EP

Kind code of ref document: A2